Sarilumab use in severe SARS-CoV-2 pneumonia

https://doi.org/10.1016/j.eclinm.2020.100553

Of the 53 SARS-CoV-2(pos) patients receiving Sarilumab, 39(73.6%) were treated in medical wards [66.7% with a single infusion; median PaO2/FiO2:146(IQR:120-212)] while 14(26.4%) in ICU [92.6% with a second infusion; median PaO2/FiO2: 112(IQR:100-141.5)].Within the medical wards, 7(17.9%) required ICU admission, 4 of whom were re-admitted to the ward within 5-8 days. At 19 days median follow-up, 89.7% of medical inpatients significantly improved (46.1% after 24 h, 61.5% after 3 days), 70.6% were discharged from the hospital and 85.7% no longer needed oxygen therapy. Within patients receiving Sarilumab in ICU, 64.2% were discharged from ICU to the ward and 35.8% were still alive at the last follow-up. Overall mortality rate was 5.7%.IL-6R inhibition appears to be a potential treatment strategy for severe SARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical outcome and good safety.

Tags: